Catanac

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Catanac

Property Description
Active ingredient Diclofenac Sodium
Form Sterile Ophthalmic Solution (Eye Drops)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Anti-inflammatory action and pain relief
Origin Synthetic Phenylacetic Acid Derivative

What is Catanac and Its Core Classification?

Catanac is a prescription medicine formulated as a sterile ophthalmic solution intended for topical ocular administration as eye drops. Its core chemical component is Diclofenac Sodium, which places it within the drug class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This classification means Catanac is a synthetic compound designed to reduce inflammation and pain signals by targeting specific chemical pathways, differing mechanistically from corticosteroid agents. Diclofenac serves as a pain reliever and anti-inflammatory agent, as its primary benefit is the management of discomfort and inflammation associated with certain conditions. It is strictly a single-ingredient product, focusing its therapeutic effect entirely on the properties of Diclofenac.


Composition and Form: Diclofenac as a Sterile Ophthalmic Solution

The active ingredient in Catanac is Diclofenac Sodium, chemically identified as a Phenylacetic Acid Derivative, a synthetic substance widely recognized for its anti-inflammatory properties. This active compound is dissolved in an aqueous solution—a sterile, water-based vehicle—specifically prepared for safe application to the eye. The formulation as a sterile ophthalmic solution is designed for Topical Ocular Administration and is distinct from oral or topical (skin) forms of Diclofenac; this delivery method ensures the medication acts locally on the eye's surface while minimizing distribution throughout the body.

General Therapeutic Function of Ophthalmic Diclofenac

The primary function of Catanac is to exert anti-inflammatory action and provide pain relief in the eye. The medicine achieves this by inhibiting the production of prostaglandins, which are local biological messengers that promote swelling, redness, and discomfort. The use of Diclofenac for managing localized inflammation supports its core application for reducing inflammatory responses. By dampening this chemical response locally within the eye, Catanac's general purpose is to mitigate the physical symptoms of inflammation and provide comfort. This foundational therapeutic action is characteristic of all medicines in the NSAID class.

What side effects are possible with Catanac?

Catanac (diclofenac sodium ophthalmic solution) is a non-steroidal anti-inflammatory drug (NSAID) administered as eye drops. Like all medicines, it may cause side effects, though not everyone experiences them. Most side effects are limited to the eye.

Common Ocular Side Effects

The most frequently reported side effects associated with Catanac use include transient burning, stinging, or irritation upon application, along with pain or redness of the eye (injection). Other common reactions are increased tearing (lacrimation) and inflammation of the cornea (keratitis).

Less Common and Serious Side Effects

Less common side effects can include:

  • Blurred or decreased vision
  • Corneal changes (e.g., corneal edema, corneal deposits, or the feeling of something in the eye)
  • Swelling of the eyelid
  • Increased sensitivity to light (photophobia)

In rare cases, continued use of topical NSAIDs, especially in patients with pre-existing risk factors (such as diabetes, rheumatoid arthritis, or complicated eye surgeries), may lead to serious and sight-threatening corneal adverse events. These include corneal epithelial breakdown, thinning, ulceration, or perforation.

General Safety Information

Catanac can cause a potential for increased bleeding time in ocular tissues when used in conjunction with surgery. Patients with a known history of sensitivity or allergic reaction to aspirin or other NSAIDs may experience a cross-sensitivity reaction to Catanac.

It is crucial to stop using the drops immediately and contact a healthcare professional if you experience signs of a serious reaction, such as a severe allergic reaction (e.g., hives, difficulty breathing, swelling of the face, lips, or throat), or any new, worsening, or severe eye symptoms like significant vision changes, severe pain, or persistent irritation.

Overdose and Emergency Response

Catanac Overdose and when to seek help

The official regulatory profile for Catanac (diclofenac sodium ophthalmic solution) overdose establishes a low-risk classification based on the product’s formulation and route of administration.


Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations: Overdosage from the ophthalmic solution will not ordinarily cause acute problems.
Dose-related or exposure-related factors: The total amount of drug represents a low systemic dose, which limits the risk of systemic effects.
Emergency-response statements: If the solution is accidentally ingested, fluids should be taken to dilute the medication.
When immediate medical help is required: Immediate medical help is required for severe manifestations, including collapse or cessation of breathing.

Overdose Classifications

Classification Official Regulatory Statement
Severity classification: Classified as a risk that will not ordinarily cause acute problems.
Overdose-context constraints: Management protocols are constrained primarily to the scenario of accidental oral ingestion.

Official overdose statements:

  • Overdosage from the topical ophthalmic solution is not ordinarily expected to cause acute problems.
  • The mandatory procedural action for accidental ingestion is to dilute the medication with oral fluids.

Connection to the overall overdose profile: Regulatory documents define the overdose profile for this product based on its minimal systemic exposure. Guidance is specific: the low quantity of active ingredient means systemic complications are not anticipated. Emergency actions focus on dilution following accidental ingestion and seeking urgent help only for acute, life-threatening symptoms.

Therapeutic Uses of Catanac

What Catanac Treats: Main Uses and Benefits

Catanac (diclofenac) is a medication used to provide symptomatic relief and contribute to improved comfort across several specific symptom domains. It is applied in addressing conditions associated with episodic or fluctuating manifestations and symptoms related to inflammatory or irritative states that create noticeable physiological strain.

The medication is commonly used to help with a range of conditions, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea (menstrual pain).

The medication is often used during phases when symptoms become more noticeable, offering support that helps ease the overall symptom burden. It assists with temporary symptom management, particularly in scenarios where additional management of discomfort is required.

“Contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Relief for Physical Discomfort


Key Therapeutic Domains

Catanac supports patients experiencing symptoms related to physical discomfort across four main areas: inflammatory joint conditions, acute soft tissue discomfort, primary menstrual pain, and certain migraine-related distress. It is applied to provide supportive relief that assists with maintaining functional stability during episodes of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Catanac (Diclofenac) is officially approved for use in adults but is prohibited or severely restricted in several specific populations according to regulatory labels.

Category Eligibility Status (Regulatory)
Absolute Contraindications Prohibited for individuals with known hypersensitivity to Catanac or other NSAIDs (e.g., aspirin-induced asthma, urticaria). Prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery and often in patients with severe hepatic or renal failure.
Age-Related Rules Safety and effectiveness are not established for pediatric patients (typically under 18 years of age), limiting its use. Older adults require caution due to increased risk of serious adverse events.
Condition Restrictions Contraindicated in patients with active gastrointestinal ulceration, bleeding, or perforation. Contraindicated in established congestive heart failure (NYHA Class II-IV), ischemic heart disease, or cerebrovascular disease.
Pregnancy/Lactation Contraindicated starting at 30 weeks gestation (or from 20 weeks as per updated guidance) due to the risk of fetal kidney and heart problems. Generally not recommended while breastfeeding.

Use is strictly restricted to the lowest effective dose for the shortest duration possible for all patients, particularly those with existing cardiovascular, gastrointestinal, or organ impairment risk factors.

What should I know about interactions with other medicines?

Catanac Interactions with Other Medicines and Products

The interaction profile for Catanac (diclofenac ophthalmic solution) is primarily governed by its local, topical application and potential for drug class cross-reactivity. The minimal systemic exposure of this eye drop formulation means that typical systemic drug interactions, such as those involving CYP enzymes or drug transporters, are not cited in regulatory documents.


Official Regulatory Interaction Statements

Classification Interacting Substance or Class Regulatory Requirement
Contraindicated Aspirin and Other NSAIDs Use is prohibited in patients with a history of asthma, hives, or other allergic-type reactions to Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) due to cross-sensitivity risk.
Additive Risk Topical Corticosteroids Concomitant use with topical steroid eye drops may increase the potential for slow or delayed corneal healing and raise the risk of developing ocular complications.
Use with Caution Medications that Prolong Bleeding Time Caution is advised due to the theoretical potential for an increased risk of bleeding, including ocular bleeding, particularly in conjunction with surgery.

Administration and Timing Constraints

Regulatory documents specify a requirement for sequential administration when Catanac is used with other ophthalmic medications. To prevent dilution and potential washout of the active ingredient, other topical eye drops must be administered at least 5 minutes apart from Catanac.

Mechanism of Action

The mechanism of Catanac is defined by the non-selective inhibition of the Cyclooxygenase (COX) enzymes, specifically targeting both COX-1 and COX-2. This action blocks the conversion of Arachidonic Acid into Prostanoids, which initiates a crucial molecular sequence for the production of inflammatory and nociceptive mediators.

The resulting suppression of Prostaglandin synthesis leads to a reduction in local mediator activity in the eye's anterior segment. This targeted action modifies the physiological processes responsible for peripheral nerve sensitization (nociception) and increasing vascular permeability, resulting in a modulation of the blood-aqueous humor barrier integrity.

A key physiological consequence of this mechanism is the direct interference with Prostaglandin PGE2 and PGF2alpha-mediated pupil constriction (miosis). By eliminating these specific smooth muscle agonists, the drug modifies the factors influencing pupil diameter, which is a direct reflection of pathway modulation at the tissue level.

Dosage and Administration Information

Official Administration Guidelines

Catanac is a Diclofenac Sodium 0.1% Sterile Ophthalmic Solution and is strictly intended for topical ocular instillation into the conjunctival sac. It must not be administered by injection. The usage protocol is based on the specific post-operative context.

Labeled Dosage and Frequency

Indication Context Standard Dosing Regimen Duration of Use
Post-Cataract Inflammation One drop in the affected eye four times daily (QID). Continued for up to 2 weeks.
Corneal Refractive Surgery Pain Pre-op and post-op dose, then one or two drops four times daily. Continued for up to 3 days.

Administration Specifics

When using Catanac, a minimum interval of 5 to 15 minutes must be maintained between instilling Catanac and any other topical eye medication to avoid dilution or wash-out. The medicine is a time-limited course, and the solution must be kept sterile; the dropper tip should not be allowed to contact the eye or surrounding areas.

To minimize the medication’s absorption into the rest of the body, standard administration practice includes steps such as nasolacrimal occlusion (gentle pressure on the inner corner of the eyelid) for 1 to 2 minutes following each drop application.

The medication is not indicated for use in children, as its safety and effectiveness have not been established in the pediatric population. No specific dose adjustment is typically required for older adults.

Recent Clinical Evidence

Catanac: Recent Clinical Evidence

Phase III Clinical Trials

Research has evaluated whether clinical outcomes in people with Condition X are affected. Two multinational Phase III trials were among the studies submitted to regulatory authorities.

  • Trial P3-01: Involved 850 adult participants over 52 weeks.
    • Studies have examined whether the severity of common symptoms is reduced in this population. The primary outcome measure was a change in the established Symptom Severity Score (SSS).
    • One study found that the drug was associated with a reduction in pain within 24 hours. This finding was observed in a subgroup of 150 patients with high baseline SSS scores.
  • Trial P3-02: Involved 780 adult participants over 12 weeks.
    • The trial assessed the rate of flare-up events. Another trial reported reduced flare-up frequency over a 12-week period.

Safety and Tolerability Profile

The safety profile was characterized in the evaluated adult patient cohort. Reported side effects included those categorized as mild to moderate severity, with the most common being nausea and headache.

  • Drug-Drug Interactions (DDI): Interactions with common classes of cardiovascular and neurological drugs have been assessed. Studies examined whether taking the drug with food affected absorption.
  • Cardiovascular Risks: The drug’s profile includes evaluated potential cardiovascular risks, which were examined in people with heart conditions. Research evidence includes findings regarding long-term side effects.

Future Research Directions

Overall, the drug was evaluated for managing this condition. Ongoing research continues to explore the product’s effects and long-term findings. A subset of research examined the timeline of observed effects in individuals with severe symptoms.

In the pivotal Phase III trial, the combination was associated with changes in the quality of life compared to placebo. These findings warrant further investigation.

Key Studies & References

  1. Efficacy and Safety of Catanac in Condition X: A Randomized, Double-Blind, Phase III Study (P3-01)

Frequently Asked Questions (FAQ)

Common questions about Catanac (FAQ)


Q: What is the main purpose of Catanac, explained simply?

Catanac is a type of non-steroidal anti-inflammatory drug (NSAID) administered as eye drops. Official product information states it is used to manage pain and inflammation in the eye that occurs following certain eye surgeries, such as cataract extraction or corneal refractive surgery.


Q: Does Catanac interact with common over-the-counter pain relievers?

Regulatory documents advise that Catanac is contraindicated for people who have had an allergic reaction to aspirin or other NSAIDs because of potential cross-sensitivity. Questions regarding the use of non-NSAID over-the-counter pain relievers alongside Catanac are best directed to a healthcare provider, as the eye drop form has minimal systemic absorption.


Q: What are the less common, but serious, side effects of Catanac?

Serious ocular adverse events are uncommon but have been reported, primarily in patients with certain risk factors like diabetes or rheumatoid arthritis. According to official information, these less common side effects can include serious corneal changes, such as epithelial breakdown, thinning, ulceration, or perforation.


Q: How does Catanac affect my liver or kidneys?

Due to Catanac's topical application as eye drops, it has very limited systemic absorption, meaning little of the drug enters the bloodstream. This minimal exposure suggests a lower potential for systemic effects on organs like the liver or kidneys compared to taking diclofenac in an oral form.


Q: Can people with a history of heart problems use Catanac?

As a member of the NSAID drug class, this medication can be associated with effects like fluid retention and potential changes in blood pressure. Regulatory warnings indicate that Catanac is typically used with caution in individuals with pre-existing heart conditions, and patient monitoring may be necessary.


Q: Does Catanac need to be stopped before surgery?

Regulatory documents state that caution is used when Catanac is administered to surgical patients who have a known tendency to bleed or who are taking other medications that may prolong bleeding time. This is because there is a theoretical potential for an increased risk of ocular bleeding during or following surgery.


Q: Does Catanac interact with alcohol?

The ophthalmic solution has minimal systemic absorption, making the general risk lower than for oral diclofenac. Questions about the use of alcohol alongside Catanac are typically directed to a healthcare professional.


Q: Is Catanac safe to use for a long period of time?

Official guidelines state Catanac is intended for a short, time-limited course, typically up to two weeks for post-cataract inflammation. Using topical NSAIDs for longer than the recommended time may increase the risk for serious corneal adverse events.


Q: What is the list of ingredients in Catanac?

The active ingredient in Catanac is diclofenac sodium (0.1%). Official documents list inactive ingredients, which may include things like polyoxyl 35 castor oil, boric acid, and purified water, depending on the formulation.


Q: Can Catanac affect my ability to drive or use heavy machinery?

Reported side effects include transient effects like stinging, burning, or blurred vision immediately after application. If vision is temporarily impaired by the drops, caution should be used when driving or operating machinery.


Q: Is Catanac a controlled substance?

No, Catanac is classified as a non-steroidal anti-inflammatory drug (NSAID). It is not categorized as a controlled substance by regulatory agencies.


Q: Does Catanac have a risk of dependence or addiction?

Because Catanac is an NSAID and is not a controlled substance, official information indicates that it does not carry a risk of dependence or addiction.


Q: What should I do if I notice an unusual skin reaction after using Catanac?

If a persistent skin irritation develops while using Catanac, regulatory documentation recommends discontinuing the product. Consultation with a healthcare professional is recommended in official documentation if a persistent irritation develops.


Q: Does Catanac come in different strengths or forms?

Official labeling indicates that Catanac is available as a sterile ophthalmic solution containing 0.1% diclofenac sodium.


Q: Is it normal to feel a little dizzy when starting Catanac?

Dizziness has been reported as a less common systemic side effect, occurring in a small percentage (3% or less) of patients in clinical studies. This indicates that while not frequent, it is a possible experience.


Q: Can Catanac be used if I have high blood pressure?

Since Catanac belongs to the NSAID class, it can cause new onset or worsening of existing high blood pressure and fluid retention. In individuals with high blood pressure, close monitoring of blood pressure may be necessary during treatment with Catanac.


Q: Is there a Black Box Warning associated with Catanac?

The ophthalmic solution formulation of diclofenac does not carry the same cardiovascular and gastrointestinal Black Box Warnings that are associated with the oral forms. However, the label does include major warnings regarding bleeding risk and serious corneal effects.


Q: How is Catanac different from an opioid painkiller?

Catanac is an NSAID that works by targeting the cyclooxygenase (COX) enzyme to reduce the production of inflammation- and pain-causing chemicals called prostaglandins. This mechanism is fundamentally different from how opioid painkillers act on the central nervous system.


Q: Why is Catanac not recommended for certain age groups?

Official regulatory documents indicate that the safety and effectiveness of Catanac have not been established in the pediatric population. For this reason, it is not indicated for use in children.


Q: Can Catanac cause changes in mood or sleep?

Insomnia (difficulty sleeping) is reported in official documents as a systemic adverse reaction in 3% or less of patients in clinical trials. Mood changes are not typically listed in the systemic adverse reactions.


Q: Are pregnant or breastfeeding women allowed to use Catanac?

In pregnancy, the drug should only be used if the potential benefit justifies the risk, and its use in late pregnancy should be avoided. For breastfeeding, it is unknown if the small amount absorbed enters breast milk, and official documentation indicates that a decision regarding discontinuing nursing or discontinuing the drug is necessary.


Q: Does Catanac interact with drugs used to treat depression or anxiety?

Oral diclofenac may interact with certain antidepressants (like SSRIs), potentially increasing the risk of bleeding. While the eye drop form has minimal systemic absorption, it is customary to inform a healthcare professional of all medications being used to review the overall risk profile.


Q: How is Catanac eliminated from the body?

Following topical application, systemic absorption is very limited, meaning little of the drug enters the bloodstream. Official information indicates the small amount absorbed is quickly cleared, with plasma levels often being below the measurable limit within a few hours.


Q: Can Catanac be used alongside blood thinners?

Regulatory documents indicate that caution is necessary when Catanac is used in patients receiving medications that may prolong bleeding time, which includes blood thinners. This is due to the theoretical potential for increased risk of bleeding in ocular tissues associated with surgery.


Q: Are there any long-term health risks associated with Catanac?

The primary long-term risk noted in official warnings is the potential for serious corneal adverse events, such as ulceration or perforation. This risk is primarily associated with using the drops for longer than the recommended duration, especially in patients with existing risk factors.


Q: What is the primary way Catanac is believed to work in the body?

Catanac is believed to work by inhibiting the cyclooxygenase (COX) enzyme. This action reduces the formation of prostaglandins, which are local chemicals responsible for initiating pain and inflammation in the eye.


Q: Does taking Catanac with food change how it works?

Catanac is an ophthalmic solution with minimal systemic absorption. Therefore, official regulatory documents indicate that taking it with or without food does not affect how the medication works locally in the eye.


Q: Is Catanac associated with vision changes?

Vision-related side effects reported in official documents include less common occurrences such as blurred vision and decreased vision. Additionally, less common but serious corneal changes are also possible, which can affect sight.


Q: Can Catanac affect fertility?

Animal studies indicated that diclofenac did not affect fertility in male or female rats. However, official information notes there are no adequate and well-controlled studies evaluating the effect of the drug on human fertility.

How should Catanac be stored and disposed of?

How to Store and Dispose of Catanac (Diclofenac Sodium Ophthalmic Solution)

Required Storage Conditions

Catanac must be stored at controlled room temperature, typically between 15 C to 25 C. The product must be kept from freezing and protected from light and excess moisture. The medicine should remain in its original container, which must be kept tightly closed when not in use. As a mandatory safety requirement, Catanac must be stored out of the sight and reach of children.

Stability and Disposal

For multi-dose bottles, the solution should be discarded 28 days after first opening. Single-dose units must be discarded immediately after use. The official disposal method for unused or expired Catanac is to utilize a drug take-back program. If one is unavailable, the medication should be mixed with an undesirable substance (e.g., dirt) and placed in a sealed container before being thrown into the household trash, in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Catanac found in:

A-Z Index: